Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS.

Ciccarelli N, Limiti S, Fabbiani M, Baldonero E, Milanini B, Lamonica S, Cauda R, Di Giambenedetto S, Silveri MC.

Appl Neuropsychol Adult. 2016 Jun 13:1-10. [Epub ahead of print]

PMID:
27292092
2.

Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE).

Milanini B, Ciccarelli N, Fabbiani M, Baldonero E, Limiti S, Gagliardini R, Borghetti A, D'Avino A, Mondi A, Colafigli M, Cauda R, Di Giambenedetto S.

Clin Neuropsychol. 2016 May 16:1-12. [Epub ahead of print]

PMID:
27180611
3.

Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.

Borghetti A, Baldin G, Ciccullo A, Gagliardini R, D'Avino A, Mondi A, Ciccarelli N, Lamonica S, Fanti I, Trecarichi E, Fabbiani M, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2016 May 4. pii: dkw147. [Epub ahead of print] No abstract available.

PMID:
27147306
4.

Cognitive reserve and neuropsychological functioning in older HIV-infected people.

Milanini B, Ciccarelli N, Fabbiani M, Limiti S, Grima P, Rossetti B, Visconti E, Tamburrini E, Cauda R, Di Giambenedetto S.

J Neurovirol. 2016 Mar 10. [Epub ahead of print]

PMID:
26965299
5.

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.

Mondi A, Fabbiani M, Ciccarelli N, Colafigli M, D'Avino A, Borghetti A, Gagliardini R, Cauda R, De Luca A, Di Giambenedetto S.

J Antimicrob Chemother. 2015;70(6):1843-9. doi: 10.1093/jac/dkv037. Epub 2015 Feb 26.

6.

Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.

Fabbiani M, Grima P, Milanini B, Mondi A, Baldonero E, Ciccarelli N, Cauda R, Silveri MC, De Luca A, Di Giambenedetto S.

Antivir Ther. 2015;20(4):441-7. doi: 10.3851/IMP2926. Epub 2014 Dec 17.

PMID:
25516553
7.

Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.

Ciccarelli N, Grima P, Fabbiani M, Baldonero E, Borghetti A, Milanini B, Limiti S, Colafigli M, Tamburrini E, Cauda R, De Luca A, Di Giambenedetto S.

Antivir Ther. 2015;20(4):433-40. doi: 10.3851/IMP2925. Epub 2014 Dec 11.

PMID:
25504667
8.

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre.

Borghetti A, Mondi A, Piccoli B, Gagliardini R, Lamonica S, Ciccarelli N, D'Avino A, Pallavicini F, Cauda R, De Luca A, Fabbiani M, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19817. doi: 10.7448/IAS.17.4.19817. eCollection 2014.

9.

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA.

Bianco C, Meini G, Rossetti B, Lamonica S, Mondi A, Belmonti S, Fanti L, Ciccarelli N, Di Giambenedetto S, Zazzi M, De Luca A.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19791. doi: 10.7448/IAS.17.4.19791. eCollection 2014.

10.

Liver fibrosis is associated with cognitive impairment in HIV-positive patients.

Ciccarelli N, Fabbiani M, Grima P, Limiti S, Fanti I, Mondi A, Gagliardini R, D'Avino A, Borghetti A, Cauda R, Di Giambenedetto S.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19722. doi: 10.7448/IAS.17.4.19722. eCollection 2014.

11.

Posterior AD-type pathology: cognitive subtypes emerging from a cluster analysis.

Cappa A, Ciccarelli N, Baldonero E, Martelli M, Silveri MC.

Behav Neurol. 2014;2014:259358. doi: 10.1155/2014/259358. Epub 2014 Jun 5.

12.

Primary progressive aphasia: linguistic patterns and clinical variants.

Silveri MC, Pravatà E, Brita AC, Improta E, Ciccarelli N, Rossi P, Colosimo C.

Brain Lang. 2014 Aug;135:57-65. doi: 10.1016/j.bandl.2014.05.004. Epub 2014 Jun 27.

PMID:
24974082
13.

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).

Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S.

Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28.

PMID:
24161018
14.

Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients.

Ciccarelli N, Fabbiani M, Grima P, Falasca K, Tana M, Baldonero E, Colafigli M, Silveri MC, Vecchiet J, Cauda R, Di Giambenedetto S.

Infection. 2013 Dec;41(6):1103-9. doi: 10.1007/s15010-013-0503-2. Epub 2013 Jul 10.

PMID:
23839213
15.

Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.

Ciccarelli N, Fabbiani M, Colafigli M, Trecarichi EM, Silveri MC, Cauda R, Murri R, De Luca A, Di Giambenedetto S.

Antivir Ther. 2013;18(2):153-60. doi: 10.3851/IMP2560. Epub 2013 Mar 13.

PMID:
23486721
16.

Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).

Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, D'Avino A, Mondi A, Cingolani A, Tamburrini E, Murri R, Navarra P, Cauda R, De Luca A.

J Antimicrob Chemother. 2013 Jun;68(6):1364-72. doi: 10.1093/jac/dkt007. Epub 2013 Jan 30.

17.

Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance.

Baldonero E, Ciccarelli N, Fabbiani M, Colafigli M, Improta E, D'Avino A, Mondi A, Cauda R, Di Giambenedetto S, Silveri MC.

BMC Psychol. 2013 Feb 27;1(1):3. doi: 10.1186/2050-7283-1-3. eCollection 2013.

18.

Effect of aging and human immunodeficiency virus infection on cognitive abilities.

Ciccarelli N, Fabbiani M, Baldonero E, Fanti I, Cauda R, Di Giambenedetto S, Silveri MC.

J Am Geriatr Soc. 2012 Nov;60(11):2048-55. doi: 10.1111/j.1532-5415.2012.04213.x. Epub 2012 Oct 30.

PMID:
23110543
19.

Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients.

Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, Di Cristo V, Colafigli M, Tamburrini E, Cauda R, Silveri MC, Grima P, Di Giambenedetto S.

HIV Med. 2013 Mar;14(3):136-44. doi: 10.1111/j.1468-1293.2012.01044.x. Epub 2012 Sep 21.

20.

Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients.

Grima P, Fabbiani M, Ciccarelli N, Tana M, Farina S, Colafigli M, Mondi A, Cauda R, Di Giambenedetto S.

J Infect. 2012 Nov;65(5):439-46. doi: 10.1016/j.jinf.2012.07.005. Epub 2012 Aug 3.

PMID:
22863903
Items per page

Supplemental Content

Loading ...
Write to the Help Desk